Items Tagged ‘xalkori’

March 29th, 2016

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations

By

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment of patients with NSCLC that have a mutation in the anaplastic lymphoma kinase (ALK) gene. Lung cancer […]

View full entry

Tags: clinical trial, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, ROS-1 gene, xalkori


November 16th, 2015

New Lab Test Enables Precision Treatment for Lung Cancer

By

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer is the most common cause of cancer-related deaths in the United States. Opdivo, a PD 1 […]

View full entry

Tags: alk, EGFR, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell, opdivo, PD-L1 levels, xalkori


December 6th, 2014

Xalkori™ (crizotinib) Targeted Therapy More Effective Than Chemotherapy for Treatment of Lung Cancer

By

A new drug Xalkori™ (crizotinib) is more beneficial than chemotherapy for certain individuals with lung cancer according to new research published in the New England Journal of Medicine. Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of developing effective new approaches to treatment. Ninety percent […]

View full entry

Tags: alk, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, xalkori